CERo Therapeutics Announces Convertible Note Financing and New Director

CERo Therapeutics Holdings ( (CERO) ) just unveiled an update.

On February 9, 2026, CERo Therapeutics Holdings issued a $937,500 principal-value convertible promissory note to Keystone Capital Partners for a purchase price of $750,000, with the ability to draw up to $1,000,000 in total. The note carries 10% annual interest, matures on July 9, 2027, and is convertible into common stock at a variable price formula, potentially resulting in shareholder dilution but bolstering the company’s near-term liquidity and financing flexibility.

The financing was executed as a private placement relying on exemptions from U.S. securities registration, with resale of conversion shares to be registered later, underscoring CERo’s continued use of structured capital markets instruments. The company’s board also expanded from six to seven members and appointed veteran capital markets and biotech finance executive Eric Francois as a director effective February 13, 2026, strengthening its governance and financial expertise ahead of the 2026 annual meeting.

The most recent analyst rating on (CERO) stock is a Hold with a $0.10 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.

More about CERo Therapeutics Holdings

CERo Therapeutics Holdings, Inc. is a Delaware-based company operating in the biotechnology and healthcare capital markets space, with a focus on accessing equity and convertible debt financing to support its activities. The company is listed in the U.S. public markets and structures its capital raises through exempt private offerings to accredited investors, reflecting an emphasis on flexible, market-driven funding solutions.

Average Trading Volume: 431,216

Technical Sentiment Signal: Sell

Current Market Cap: $896.9K

For a thorough assessment of CERO stock, go to TipRanks’ Stock Analysis page.